

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Simon J. Mantell, et al. :

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned

FILING DATE: Herewith : Group Art Unit: To Be Assigned

TITLE: 2-Aminocarbonyl-9H-purine Derivatives :

Mail Stop Patent Applications
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: October 1, 2003

Respectfully submitted,

Robert T. Ronau
Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-5910

EXPRESS MAIL NO. 50272781973US

| | | | | | | | | | | | | | | |
|---|----|-----------------|--|------------------------------------|---|---|---|---------------------------|-------------|---------------|-------|----------|-------------------------------|----|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | | ATTY. DOCKET NO. PC10921B | | | | SERIAL NO. To Be Assigned | | | | | | |
| | | | | APPLICANT Simon J. Mantell, et al. | | | | | | | | | | |
| | | | | FILING DATE Herewith | | | | GROUP To Be Assigned | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| DOCUMENT NUMBER | | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | WO | 9 | 9 | 6 | 5 | 8 | 9 | 5 | 23 Dec 1999 | International | C07D | 401/104 | | |
| | WO | 9 | 8 | 5 | 5 | 1 | 4 | 8 | 10 Dec 1998 | International | A61K | 47/48 | | |
| | WO | 9 | 4 | 0 | 2 | 5 | 1 | 8 | 3 Feb 1994 | International | C08B | 37/16 | | |
| | WO | 9 | 1 | 1 | 1 | 1 | 7 | 2 | 8 Aug 1991 | International | A61K | 9/00 | | |
| | | | | | | | | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| | | | Jacobson, et al., J. of Medicinal Chemistry, 1992, 35(3), pg 407-422 | | | | | | | | | | | |
| | | | Olsson, et al., J. of Medicinal Chemistry, 1986, 29(9), pg 1683-1689 | | | | | | | | | | | |
| | | | Berge et al., J. Pharm. Sci, 66, pg 1-19 | | | | | | | | | | | |
| | | | Monatsh, Chem., 88, pg 35, 1957 | | | | | | | | | | | |
| | | | Justus Liebigs Ann. Che., 648, pg 72-82 | | | | | | | | | | | |
| | | | J. Chem., Soc., Perkin Trans., 1, 11, pg 1205-1211, 1996 | | | | | | | | | | | |
| | | | J. Amer. Chem. Soc, 80, pg 5168-5173, 1958 | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| <div style="display: flex; justify-content: space-between;"> <div>EXAMINER</div> <div>DATE CONSIDERED</div> </div> | | | | | | | | | | | | | | |
| <small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small> | | | | | | | | | | | | | | |

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. 5027278197345

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99